FindTrial
Sign In

A new prognostic model combined with PET/CT SUVmax P-FLIPI for follicular lymphoma

A new prognostic model combined with PET/CT SUVmax P-FLIPI for follicular lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043613
Enrollment
Unknown
Registered
2021-02-23
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular lymphoma

Interventions

Group 1:none
Group 2:none

Sponsors

Sichuan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older; 2. Patients with grade 1, grade 2 or grade 3a of follicular lymphoma confirmed by histopathology; 3. Have treatment indications and accept standard first-line treatment; 4. There are pre-treatment PET/CT examination results and complete patient general conditions and laboratory examination results (including FLIPI, FLIPI2 related indicators).

Exclusion criteria

Exclusion criteria: 1. Combined with DLBCL or FL 3b components at the time of diagnosis; 2. Have a history of any other malignant tumors; 3. The PET/CT test result is negative before treatment; 4. Lack of complete follow-up data.

Design outcomes

Primary

MeasureTime frame
SUV max;overall survival;progression free survival;—

Countries

China

Contacts

Public ContactTongyu Lin

Sichuan Cancer Hospital

tongyulin@hotmail.com+86 28-85420816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026